These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005 [TBL] [Abstract][Full Text] [Related]
44. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855 [TBL] [Abstract][Full Text] [Related]
45. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Liao BC; Lin CC; Yang JC Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025 [TBL] [Abstract][Full Text] [Related]
46. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. Lund-Iversen M; Kleinberg L; Fjellbirkeland L; Helland Å; Brustugun OT J Thorac Oncol; 2012 Sep; 7(9):1471-3. PubMed ID: 22895145 [TBL] [Abstract][Full Text] [Related]
47. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related]
49. Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer. Qu L; Li L; Zheng X; Fu H; Tang C; Qin H; Li X; Wang H; Li J; Wang W; Yang S; Wang L; Zhao G; Lv P; Lei Y; Zhang M; Gao H; Song S; Liu X Oncotarget; 2017 Jul; 8(28):45807-45824. PubMed ID: 28496005 [TBL] [Abstract][Full Text] [Related]
50. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
51. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Li K; Yang M; Liang N; Li S Oncol Rep; 2017 Mar; 37(3):1347-1358. PubMed ID: 28184913 [TBL] [Abstract][Full Text] [Related]
52. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution. Koyama N; Watanabe Y; Iwai Y; Kawamura R; Miwa C; Nagai Y; Hagiwara K; Koyama S Chemotherapy; 2017; 62(3):151-158. PubMed ID: 28110331 [TBL] [Abstract][Full Text] [Related]
53. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199 [TBL] [Abstract][Full Text] [Related]
54. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Wong KK Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579 [TBL] [Abstract][Full Text] [Related]
55. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Kao HF; Lin CC; Yang JC Future Oncol; 2013 Jul; 9(7):991-1003. PubMed ID: 23837762 [TBL] [Abstract][Full Text] [Related]
56. Emerging treatment for advanced lung cancer with EGFR mutation. Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235 [TBL] [Abstract][Full Text] [Related]
57. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835 [TBL] [Abstract][Full Text] [Related]
58. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. Xu J; Zhang Y; Jin B; Chu T; Dong X; Yang H; Wu D; Lou Y; Zhang X; Wang H; Han B J Cancer Res Clin Oncol; 2016 Jun; 142(6):1325-30. PubMed ID: 26942444 [TBL] [Abstract][Full Text] [Related]
60. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y; Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]